{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:34:02Z","timestamp":1772138042259,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12185-022-03520-8","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T04:27:34Z","timestamp":1672201654000},"page":"748-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR\/ABL1-positive acute lymphoblastic leukemia cells"],"prefix":"10.1007","volume":"117","author":[{"given":"Haruka","family":"Hiroki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshi","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Morio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-9184","authenticated-orcid":false,"given":"Masatoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"issue":"4","key":"3520_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/gcc.10250","volume":"38","author":"M Masutani","year":"2003","unstructured":"Masutani M, Nakagama H, Sugimura T. Poly(ADP-ribose) and carcinogenesis. Genes Chromosomes Cancer. 2003;38(4):339\u201348. https:\/\/doi.org\/10.1002\/gcc.10250.","journal-title":"Genes Chromosomes Cancer"},{"issue":"19","key":"3520_CR2","doi-asserted-by":"publisher","first-page":"5526","DOI":"10.1093\/nar\/gkg761","volume":"31","author":"SF El-Khamisy","year":"2003","unstructured":"El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003;31(19):5526\u201333.","journal-title":"Nucleic Acids Res"},{"issue":"35","key":"3520_CR3","doi-asserted-by":"publisher","first-page":"32411","DOI":"10.1074\/jbc.C100292200","volume":"276","author":"R Prasad","year":"2001","unstructured":"Prasad R, Lavrik OI, Kim SJ, Kedar P, Yang XP, Vande Berg BJ, et al. DNA polymerase beta -mediated long patch base excision repair Poly (ADP-ribose)polymerase-1 stimulates strand displacement DNA synthesis. J Biol Chem. 2001;276(35):32411\u20134. https:\/\/doi.org\/10.1074\/jbc.C100292200.","journal-title":"J Biol Chem"},{"issue":"17","key":"3520_CR4","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/emboj.2009.206","volume":"28","author":"HE Bryant","year":"2009","unstructured":"Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009;28(17):2601\u201315. https:\/\/doi.org\/10.1038\/emboj.2009.206.","journal-title":"EMBO J"},{"issue":"7035","key":"3520_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137. https:\/\/doi.org\/10.1038\/nature03443.","journal-title":"Nature"},{"issue":"4","key":"3520_CR6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18(4):930\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1613.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3520_CR7","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/sj.leu.2401855","volume":"14","author":"HF Salloukh","year":"2000","unstructured":"Salloukh HF, Laneuville P. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia. 2000;14(8):1401\u20134. https:\/\/doi.org\/10.1038\/sj.leu.2401855.","journal-title":"Leukemia"},{"issue":"2","key":"3520_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11899-007-0010-6","volume":"2","author":"T Skorski","year":"2007","unstructured":"Skorski T. Genomic instability: The cause and effect of BCR\/ABL tyrosine kinase. Curr Hematol Malig Rep. 2007;2(2):69\u201374. https:\/\/doi.org\/10.1007\/s11899-007-0010-6.","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"3520_CR9","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1182\/blood-2002-10-3011","volume":"101","author":"E Deutsch","year":"2003","unstructured":"Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC, et al. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood. 2003;101(11):4583\u20138. https:\/\/doi.org\/10.1182\/blood-2002-10-3011.","journal-title":"Blood"},{"key":"3520_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.canlet.2016.11.021","volume":"386","author":"J Piao","year":"2017","unstructured":"Piao J, Takai S, Kamiya T, Inukai T, Sugita K, Ohyashiki K, et al. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells. Cancer Lett. 2017;386:131\u201340. https:\/\/doi.org\/10.1016\/j.canlet.2016.11.021.","journal-title":"Cancer Lett"},{"issue":"2","key":"3520_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","volume":"141","author":"SF Bunting","year":"2010","unstructured":"Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141(2):243\u201354. https:\/\/doi.org\/10.1016\/j.cell.2010.03.012.","journal-title":"Cell"},{"issue":"7553","key":"3520_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature14328","volume":"521","author":"G Xu","year":"2015","unstructured":"Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015;521(7553):541\u20134. https:\/\/doi.org\/10.1038\/nature14328.","journal-title":"Nature"},{"issue":"20","key":"3520_CR13","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","volume":"16","author":"T Skorski","year":"1997","unstructured":"Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al. Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway. EMBO J. 1997;16(20):6151\u201361. https:\/\/doi.org\/10.1093\/emboj\/16.20.6151.","journal-title":"EMBO J"},{"issue":"42","key":"3520_CR14","doi-asserted-by":"publisher","first-page":"35767","DOI":"10.1074\/jbc.M507075200","volume":"280","author":"A Tapodi","year":"2005","unstructured":"Tapodi A, Debreceni B, Hanto K, Bognar Z, Wittmann I, Gallyas F Jr, et al. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J Biol Chem. 2005;280(42):35767\u201375. https:\/\/doi.org\/10.1074\/jbc.M507075200.","journal-title":"J Biol Chem"},{"issue":"10","key":"3520_CR15","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.18632\/oncotarget.1952","volume":"5","author":"CK Sun","year":"2014","unstructured":"Sun CK, Zhang F, Xiang T, Chen Q, Pandita TK, Huang Y, et al. Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers. Oncotarget. 2014;5(10):3375\u201385. https:\/\/doi.org\/10.18632\/oncotarget.1952.","journal-title":"Oncotarget"},{"issue":"16","key":"3520_CR16","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1073\/pnas.0914242107","volume":"107","author":"A Kumar","year":"2010","unstructured":"Kumar A, Fernandez-Capetillo O, Carrera AC. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc Natl Acad Sci U S A. 2010;107(16):7491\u20136. https:\/\/doi.org\/10.1073\/pnas.0914242107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"29","key":"3520_CR17","doi-asserted-by":"publisher","first-page":"21206","DOI":"10.1074\/jbc.M703042200","volume":"282","author":"GD Kao","year":"2007","unstructured":"Kao GD, Jiang Z, Fernandes AM, Gupta AK, Maity A. Inhibition of phosphatidylinositol-3-OH kinase\/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem. 2007;282(29):21206\u201312. https:\/\/doi.org\/10.1074\/jbc.M703042200.","journal-title":"J Biol Chem"},{"issue":"11","key":"3520_CR18","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","volume":"2","author":"YH Ibrahim","year":"2012","unstructured":"Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036\u201347. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0348.","journal-title":"Cancer Discov"},{"issue":"1","key":"3520_CR19","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1186\/s12885-017-3639-0","volume":"17","author":"CA Philip","year":"2017","unstructured":"Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 2017;17(1):638. https:\/\/doi.org\/10.1186\/s12885-017-3639-0.","journal-title":"BMC Cancer"},{"issue":"1","key":"3520_CR20","doi-asserted-by":"publisher","first-page":"9966","DOI":"10.1038\/s41598-018-27767-6","volume":"8","author":"M Tamai","year":"2018","unstructured":"Tamai M, Inukai T, Kojika S, Abe M, Kagami K, Harama D, et al. T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system. Sci Rep. 2018;8(1):9966. https:\/\/doi.org\/10.1038\/s41598-018-27767-6.","journal-title":"Sci Rep"},{"issue":"12","key":"3520_CR21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/sj.gt.3301206","volume":"7","author":"S Morita","year":"2000","unstructured":"Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7(12):1063\u20136. https:\/\/doi.org\/10.1038\/sj.gt.3301206.","journal-title":"Gene Ther"},{"issue":"3","key":"3520_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621\u201381. https:\/\/doi.org\/10.1124\/pr.58.3.10.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"3520_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635.","journal-title":"Bioinformatics"},{"issue":"1","key":"3520_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616.","journal-title":"Bioinformatics"},{"issue":"43","key":"3520_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3520_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2105-10-48","volume":"10","author":"E Eden","year":"2009","unstructured":"Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009;10:48. https:\/\/doi.org\/10.1186\/1471-2105-10-48.","journal-title":"BMC Bioinformatics"},{"issue":"7","key":"3520_CR27","doi-asserted-by":"publisher","first-page":"e21800","DOI":"10.1371\/journal.pone.0021800","volume":"6","author":"F Supek","year":"2011","unstructured":"Supek F, Bosnjak M, Skunca N, Smuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One. 2011;6(7):e21800. https:\/\/doi.org\/10.1371\/journal.pone.0021800.","journal-title":"PLoS One"},{"issue":"4946","key":"3520_CR28","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079\u201382. https:\/\/doi.org\/10.1126\/science.2408149.","journal-title":"Science"},{"issue":"15","key":"3520_CR29","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1002\/cncr.34270","volume":"128","author":"M Takagi","year":"2022","unstructured":"Takagi M, Ogawa C, Iehara T, Aoki-Nogami Y, Ishibashi E, Imai M, et al. First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors. Cancer. 2022;128(15):2949\u201357. https:\/\/doi.org\/10.1002\/cncr.34270.","journal-title":"Cancer"},{"issue":"7191","key":"3520_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110\u20134. https:\/\/doi.org\/10.1038\/nature06866.","journal-title":"Nature"},{"issue":"2","key":"3520_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334. https:\/\/doi.org\/10.1056\/NEJMoa0900212.","journal-title":"N Engl J Med"},{"key":"3520_CR32","doi-asserted-by":"publisher","unstructured":"Padella A, Ghelli Luserna Di Rora A, Marconi G, Ghetti M, Martinelli G, Simonetti G. (2022) Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. J Hematol Oncol 15 (1):10 https:\/\/doi.org\/10.1186\/s13045-022-01228-0.","DOI":"10.1186\/s13045-022-01228-0"},{"issue":"12","key":"3520_CR33","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/nm.3993","volume":"21","author":"MT Esposito","year":"2015","unstructured":"Esposito MT, Zhao L, Fung TK, Rane JK, Wilson A, Martin N, et al. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Nat Med. 2015;21(12):1481\u201390. https:\/\/doi.org\/10.1038\/nm.3993.","journal-title":"Nat Med"},{"issue":"3","key":"3520_CR34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbadis.2014.12.001","volume":"1852","author":"I Faraoni","year":"2015","unstructured":"Faraoni I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, et al. BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. Biochim Biophys Acta. 2015;1852(3):462\u201372. https:\/\/doi.org\/10.1016\/j.bbadis.2014.12.001.","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"3520_CR35","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1080\/10428194.2017.1397662","volume":"59","author":"Y Dasgupta","year":"2018","unstructured":"Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K, Mullighan CG, et al. Drugging DNA repair to target T-ALL cells. Leuk Lymphoma. 2018;59(7):1746\u20139. https:\/\/doi.org\/10.1080\/10428194.2017.1397662.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3520_CR36","first-page":"1849","volume":"34","author":"E Jasek","year":"2014","unstructured":"Jasek E, Gajda M, Lis GJ, Jasinska M, Litwin JA. Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines. Anticancer Res. 2014;34(4):1849\u201356.","journal-title":"Anticancer Res"},{"issue":"14","key":"3520_CR37","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/onc.2012.203","volume":"32","author":"LA Tobin","year":"2013","unstructured":"Tobin LA, Robert C, Rapoport AP, Gojo I, Baer MR, Tomkinson AE, et al. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene. 2013;32(14):1784\u201393. https:\/\/doi.org\/10.1038\/onc.2012.203.","journal-title":"Oncogene"},{"issue":"4","key":"3520_CR38","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1080\/10428194.2018.1520988","volume":"60","author":"M Nieborowska-Skorska","year":"2019","unstructured":"Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, et al. Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leuk Lymphoma. 2019;60(4):1098\u2013101. https:\/\/doi.org\/10.1080\/10428194.2018.1520988.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3520_CR39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/CAD.0000000000000467","volume":"28","author":"LY Xiao","year":"2017","unstructured":"Xiao LY, Kan WM. Poly ADP-ribose polymerase inhibition suppresses cisplatin toxicity in chronic myeloid leukemia cells. Anticancer Drugs. 2017;28(3):316\u201321. https:\/\/doi.org\/10.1097\/CAD.0000000000000467.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"3520_CR40","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/1078-0432.CCR-16-1274","volume":"23","author":"KW Pratz","year":"2017","unstructured":"Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, et al. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clin Cancer Res. 2017;23(4):899\u2013907. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1274.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3520_CR41","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/1078-0432.CCR-16-0984","volume":"23","author":"I Gojo","year":"2017","unstructured":"Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, et al. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clin Cancer Res. 2017;23(3):697\u2013706. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0984.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3520_CR42","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/s0006-2952(03)00077-7","volume":"65","author":"B Veres","year":"2003","unstructured":"Veres B, Gallyas F Jr, Varbiro G, Berente Z, Osz E, Szekeres G, et al. Decrease of the inflammatory response and induction of the Akt\/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem Pharmacol. 2003;65(8):1373\u201382. https:\/\/doi.org\/10.1016\/s0006-2952(03)00077-7.","journal-title":"Biochem Pharmacol"},{"issue":"30","key":"3520_CR43","doi-asserted-by":"publisher","first-page":"E4338","DOI":"10.1073\/pnas.1522223113","volume":"113","author":"A Juvekar","year":"2016","unstructured":"Juvekar A, Hu H, Yadegarynia S, Lyssiotis CA, Ullas S, Lien EC, et al. Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. Proc Natl Acad Sci U S A. 2016;113(30):E4338\u201347. https:\/\/doi.org\/10.1073\/pnas.1522223113.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3520_CR44","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-15-1772","volume":"22","author":"W Mo","year":"2016","unstructured":"Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, et al. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22(7):1699\u2013712. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1772.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3520_CR45","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","volume":"20","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, et al. Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20(4):570\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(18)30905-7.","journal-title":"Lancet Oncol"},{"key":"3520_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ceb.2017.02.007","volume":"45","author":"EC Lien","year":"2017","unstructured":"Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017;45:62\u201371. https:\/\/doi.org\/10.1016\/j.ceb.2017.02.007.","journal-title":"Curr Opin Cell Biol"},{"issue":"6","key":"3520_CR47","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1172\/JCI90825","volume":"127","author":"M Nieborowska-Skorska","year":"2017","unstructured":"Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017;127(6):2392\u2013406. https:\/\/doi.org\/10.1172\/JCI90825.","journal-title":"J Clin Invest"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03520-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03520-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03520-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T13:22:07Z","timestamp":1682083327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03520-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["3520"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03520-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"1 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}